Guangdong VTR Bio-Tech Co., Ltd. (SHE:300381)
China · Delayed Price · Currency is CNY 6.77
-0.04 (-0.59%)
At close: Feb 13, 2026
Guangdong VTR Bio-Tech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 826.13 | 821.47 | 790.19 | 1,149 | 1,838 | 1,903 |
Other Revenue | 4.73 | 4.73 | 5.83 | 24.81 | 53.95 | 11.98 |
| 830.87 | 826.2 | 796.02 | 1,174 | 1,892 | 1,915 | |
Revenue Growth (YoY) | 3.46% | 3.79% | -32.20% | -37.95% | -1.18% | -6.51% |
Cost of Revenue | 462.36 | 460.33 | 459.12 | 816.91 | 1,217 | 1,188 |
Gross Profit | 368.5 | 365.87 | 336.9 | 357.1 | 675.22 | 726.32 |
Selling, General & Admin | 256.42 | 249.87 | 273.98 | 329.93 | 465.35 | 328.93 |
Research & Development | 106.01 | 109.32 | 99.82 | 99.87 | 129.78 | 122.83 |
Other Operating Expenses | 11.1 | 2.85 | 8.72 | 16.36 | 24.61 | 21.93 |
Operating Expenses | 372.71 | 363.48 | 365.74 | 445.99 | 654.69 | 488.05 |
Operating Income | -4.21 | 2.4 | -28.83 | -88.89 | 20.53 | 238.27 |
Interest Expense | -5.12 | -6.51 | -2.83 | -19.76 | -34.4 | -46.57 |
Interest & Investment Income | 14.86 | 15.5 | 27.89 | 175.88 | 1.78 | 11.55 |
Currency Exchange Gain (Loss) | 2.66 | 2.66 | 0.65 | 15.31 | -9.01 | -11.87 |
Other Non Operating Income (Expenses) | -9.18 | -0.87 | -0.24 | -1.87 | -2.65 | -2.54 |
EBT Excluding Unusual Items | -0.99 | 13.18 | -3.35 | 80.67 | -23.76 | 188.84 |
Impairment of Goodwill | - | - | - | - | -80.83 | - |
Gain (Loss) on Sale of Investments | 0.92 | 9.36 | 5.38 | 8.89 | -2.28 | - |
Gain (Loss) on Sale of Assets | -2.53 | 3.01 | 0.05 | -0.06 | -0.23 | 0.01 |
Asset Writedown | -8.05 | -7.87 | -12.95 | -0.43 | -1.64 | -1.71 |
Other Unusual Items | 13.6 | 14.09 | 12.15 | 16 | 20.02 | 44.83 |
Pretax Income | 2.96 | 31.78 | 1.28 | 105.07 | -88.72 | 231.97 |
Income Tax Expense | -4.64 | -0.17 | 0.13 | 67.55 | -3.29 | 29.64 |
Earnings From Continuing Operations | 7.6 | 31.95 | 1.15 | 37.52 | -85.43 | 202.34 |
Minority Interest in Earnings | -1.1 | -0.86 | -11.9 | -19.29 | -33.48 | -40.63 |
Net Income | 6.5 | 31.09 | -10.75 | 18.23 | -118.91 | 161.71 |
Net Income to Common | 6.5 | 31.09 | -10.75 | 18.23 | -118.91 | 161.71 |
Net Income Growth | -66.94% | - | - | - | - | 26.81% |
Shares Outstanding (Basic) | 491 | 490 | 491 | 490 | 490 | 466 |
Shares Outstanding (Diluted) | 491 | 490 | 491 | 490 | 490 | 468 |
Shares Change (YoY) | -0.08% | -0.09% | 0.15% | -0.01% | 4.75% | 10.41% |
EPS (Basic) | 0.01 | 0.06 | -0.02 | 0.04 | -0.24 | 0.35 |
EPS (Diluted) | 0.01 | 0.06 | -0.02 | 0.04 | -0.24 | 0.35 |
EPS Growth | -66.92% | - | - | - | - | 14.85% |
Free Cash Flow | -262.43 | -308.2 | -239.77 | 51.99 | 53.95 | 120.68 |
Free Cash Flow Per Share | -0.54 | -0.63 | -0.49 | 0.11 | 0.11 | 0.26 |
Dividend Per Share | 0.100 | 0.100 | 0.060 | 0.100 | 0.100 | 0.070 |
Dividend Growth | 66.67% | 66.67% | -40.00% | - | 42.86% | 16.67% |
Gross Margin | 44.35% | 44.28% | 42.32% | 30.42% | 35.69% | 37.93% |
Operating Margin | -0.51% | 0.29% | -3.62% | -7.57% | 1.08% | 12.44% |
Profit Margin | 0.78% | 3.76% | -1.35% | 1.55% | -6.28% | 8.45% |
Free Cash Flow Margin | -31.59% | -37.30% | -30.12% | 4.43% | 2.85% | 6.30% |
EBITDA | 107.82 | 114.28 | 82.84 | 48.96 | 188.39 | 393.59 |
EBITDA Margin | 12.98% | 13.83% | 10.41% | 4.17% | 9.96% | 20.56% |
D&A For EBITDA | 112.03 | 111.88 | 111.68 | 137.85 | 167.86 | 155.32 |
EBIT | -4.21 | 2.4 | -28.83 | -88.89 | 20.53 | 238.27 |
EBIT Margin | -0.51% | 0.29% | -3.62% | -7.57% | 1.08% | 12.44% |
Effective Tax Rate | - | - | 9.92% | 64.29% | - | 12.78% |
Revenue as Reported | 830.87 | 826.2 | 796.02 | 1,174 | 1,892 | 1,915 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.